TR200100623T2 - 5-Tia-w-ikameli fenil-prostaglandin türevleri, bunları üretme yöntemleri ve müessir madde olarak bunları ihtiva eden ilaçlar - Google Patents

5-Tia-w-ikameli fenil-prostaglandin türevleri, bunları üretme yöntemleri ve müessir madde olarak bunları ihtiva eden ilaçlar

Info

Publication number
TR200100623T2
TR200100623T2 TR2001/00623T TR200100623T TR200100623T2 TR 200100623 T2 TR200100623 T2 TR 200100623T2 TR 2001/00623 T TR2001/00623 T TR 2001/00623T TR 200100623 T TR200100623 T TR 200100623T TR 200100623 T2 TR200100623 T2 TR 200100623T2
Authority
TR
Turkey
Prior art keywords
substituted phenyl
tia
producing
methods
active substance
Prior art date
Application number
TR2001/00623T
Other languages
English (en)
Inventor
Maruyama Toru
Ohuchida Shuichi
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Publication of TR200100623T2 publication Critical patent/TR200100623T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut bulus 5-tia-w-ikameli fenil-prostaglandin E türevlerine iliskindir. Daha hususiyetle belirtmek gerekirse, formül (I) 5-tia-w-ikameli fenil-prostaglandin E türevlerine iliskin bir bulustur: Sekil var
TR2001/00623T 1998-07-15 1999-07-14 5-Tia-w-ikameli fenil-prostaglandin türevleri, bunları üretme yöntemleri ve müessir madde olarak bunları ihtiva eden ilaçlar TR200100623T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20075298 1998-07-15

Publications (1)

Publication Number Publication Date
TR200100623T2 true TR200100623T2 (tr) 2001-06-21

Family

ID=16429595

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00623T TR200100623T2 (tr) 1998-07-15 1999-07-14 5-Tia-w-ikameli fenil-prostaglandin türevleri, bunları üretme yöntemleri ve müessir madde olarak bunları ihtiva eden ilaçlar

Country Status (21)

Country Link
US (1) US6462081B1 (tr)
EP (1) EP1097922B1 (tr)
JP (1) JP3174563B2 (tr)
KR (1) KR100598660B1 (tr)
CN (1) CN1173945C (tr)
AT (1) ATE291013T1 (tr)
AU (1) AU763668B2 (tr)
BR (1) BR9912813B1 (tr)
CA (1) CA2336952C (tr)
DE (1) DE69924258T2 (tr)
DK (1) DK1097922T3 (tr)
ES (1) ES2239448T3 (tr)
HU (1) HUP0204170A3 (tr)
NO (1) NO327781B1 (tr)
NZ (1) NZ509293A (tr)
PT (1) PT1097922E (tr)
RU (1) RU2220135C2 (tr)
TR (1) TR200100623T2 (tr)
TW (1) TWI249520B (tr)
WO (1) WO2000003980A1 (tr)
ZA (1) ZA200100295B (tr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
EP1226825A4 (en) * 1999-10-07 2004-08-11 Ono Pharmaceutical Co MEDICINE FOR ERECTILE DYSFUNCTION
BR0015781A (pt) * 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
KR20020067594A (ko) * 2000-01-05 2002-08-22 오노 야꾸힝 고교 가부시키가이샤 5-티아-ω-치환 페닐-프로스타글란딘 Ｅ-알콜, 이들의제조 방법 및 이들을 유효 성분으로서 함유하는 약제
PT1132086E (pt) * 2000-01-31 2006-09-29 Pfizer Prod Inc Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6586462B2 (en) * 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
EP1408961B1 (en) * 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
CN101921220B (zh) * 2001-07-23 2013-05-22 小野药品工业株式会社 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
NZ531153A (en) * 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
JP2003078830A (ja) * 2001-09-03 2003-03-14 Sony Corp デジタル放送受信装置および通信情報伝送方法
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
DE60222168T2 (de) * 2001-10-31 2008-05-15 Medical Research Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
WO2003041717A1 (fr) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
GB0208785D0 (en) * 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US20050239872A1 (en) * 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
CA2465103C (en) * 2002-08-09 2011-04-26 Taisho Pharmaceutical Co., Ltd. Use of a prostaglandin derivative as an anti-pruritic agent
EP1563846B1 (en) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
JP4477504B2 (ja) * 2002-11-13 2010-06-09 大正製薬株式会社 鎮痒剤
NZ541603A (en) * 2003-02-07 2008-03-28 Ono Pharmaceutical Co Carbonyl phenyl propanoic acid derivative compounds
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
CA2513652A1 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
WO2005012232A2 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
CN1946391A (zh) * 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
EP1782830A4 (en) * 2004-08-10 2009-07-29 Ono Pharmaceutical Co PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
JPWO2006075690A1 (ja) * 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
KR20080000647A (ko) 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
US7511168B2 (en) * 2006-01-18 2009-03-31 Shih-Yi Wei Processes and intermediates for the preparations of prostaglandins
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
JP5262720B2 (ja) 2006-10-26 2013-08-14 小野薬品工業株式会社 貼付剤
NZ577109A (en) 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
JP2012507552A (ja) 2008-10-29 2012-03-29 アエリエ・ファーマシューティカルズ・インコーポレーテッド プロスタグラジンのアミノ酸塩
KR101172638B1 (ko) 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
PH12013500205A1 (en) * 2010-07-30 2017-08-23 Allergan Inc Compounds and methods for skin repair
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2012112757A2 (en) 2011-02-17 2012-08-23 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814527A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
HUE031885T2 (en) 2012-07-19 2017-08-28 Cayman Chemical Co Inc Difluoro lactam preparations for EP4-mediated osteo-related diseases and conditions
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2018183911A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58198466A (ja) 1982-05-12 1983-11-18 Teijin Ltd ５−チアプロスタグランジン類およびその製造法
JPH072711B2 (ja) * 1986-09-24 1995-01-18 帝人株式会社 プロスタグランジンｅ▲下１▼誘導体の製造法
EP0386901A1 (en) * 1989-02-20 1990-09-12 Ono Pharmaceutical Co., Ltd. Novel 5-hetero-6-oxo-PGE derivatives
JPH03223244A (ja) * 1989-02-20 1991-10-02 Ono Pharmaceut Co Ltd ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤
JP3579448B2 (ja) * 1993-12-29 2004-10-20 大正製薬株式会社 プロスタグランジン誘導体、その塩およびその使用

Also Published As

Publication number Publication date
JP3174563B2 (ja) 2001-06-11
ATE291013T1 (de) 2005-04-15
NO327781B1 (no) 2009-09-21
BR9912813A (pt) 2001-05-02
CN1312796A (zh) 2001-09-12
US6462081B1 (en) 2002-10-08
EP1097922A4 (en) 2003-02-12
CN1173945C (zh) 2004-11-03
RU2220135C2 (ru) 2003-12-27
KR100598660B1 (ko) 2006-07-13
CA2336952C (en) 2009-09-15
TWI249520B (en) 2006-02-21
WO2000003980A1 (fr) 2000-01-27
EP1097922B1 (en) 2005-03-16
ZA200100295B (en) 2002-07-10
AU4651899A (en) 2000-02-07
DK1097922T3 (da) 2005-05-30
KR20010053386A (ko) 2001-06-25
DE69924258D1 (de) 2005-04-21
NO20010213L (no) 2001-03-15
NO20010213D0 (no) 2001-01-12
CA2336952A1 (en) 2000-01-27
NZ509293A (en) 2003-05-30
BR9912813B1 (pt) 2010-11-30
DE69924258T2 (de) 2006-01-26
ES2239448T3 (es) 2005-09-16
HUP0204170A2 (hu) 2003-04-28
EP1097922A1 (en) 2001-05-09
HUP0204170A3 (en) 2005-03-29
AU763668B2 (en) 2003-07-31
PT1097922E (pt) 2005-06-30

Similar Documents

Publication Publication Date Title
TR200001645T2 (tr) Retinoyik asit taklidi anilürler.
DK0931788T3 (da) Metalloproteasehæmmere
ES8701733A1 (es) Procedimiento para detectar peroxido de hidrogeno o sustancias formadoras de peroxido de hidrogeno
TR199800585T2 (tr) COX-2 Inhibitörleri Olarak (Metilsülfonil)Fenil-2-(5H)-Furanonlar.
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
TR200002366T2 (tr) Herbisit aktif 3-hidroksi-4-aril-5-oksopirazolin türevleri.
DK0944643T3 (da) Oxyiminopregnancarbolactoner.
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
IT8821542A0 (it) Composti attivi come inibitori della biosintesi del colesterolo.
ATE282600T1 (de) Salpetersäuresalze von antihypertensiven arzneimitteln
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
NO981393L (no) Guanidinoproteasehemmere
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
DE69807073D1 (de) Herstellung von tri-iodo-benzol-verbindungen
TR200001121T2 (tr) Antiromatizmal madde.
ATE47135T1 (de) Antikonvulsive mittel.
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
SV1998000088A (es) Compuestos farmaceuticos
EA200400709A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1